It has helped hundreds of women with ovarian cancer get information that enabled their physician to optimize their treatment plan.
The results of this companion diagnostic test could make a significant difference in treatment options for women who have been diagnosed with ovarian cancer.
The cost of BRACAnalysisCDx is reimbursed by most insurance plans.
Are you considering testing?
This is not a test for cancer: it is a test that can tell you if you are eligible for the PARP inhibitor Lynparza (olaparib).
Knowing your BRCA status can help you and your doctor make better, more informed decisions about your treatment plan.
If you are a woman with ovarian cancer, you should consider getting BRACAnalysis CDx to enable your physician to personalize your treatment plan.
BRCA testing in epithelial ovarian cancer patients is considered “medically necessary” and is covered by major insurance providers.
97% of newly diagnosed patients with ovarian cancer received insurance coverage for BRCA testing with an out-of-pocket average of $28.3
Myriad myRisk™ and BRACAnalysis® testing performed in our CLIA laboratory both provide options for physicians in assessing BRCA status, but Myriad can only market BRACAnalysis CDx as the companion diagnostic to Lynparza per FDA regulation. If your BRCA status has been previously determined, talk to your physician about whether you should be retested. Factors that may influence your physician’s decision to retest include whether your previous BRCA test included both full sequencing and large rearrangement testing.